Home
Alector

Alector Market Share Analysis for January 2026

All candidate activity and open positions are managed strictly through our Talent Acquisition department.

Health > Biotechnology and Pharmaceuticals

Domainalector.com

Year Founded2013

Employees51 - 200

Annual Revenue$100M - $200M

Alector

Alector (including company regionals)

alector.com

See more website traffic and engagement information

Alector Revenue up to January 2026 is 100M - 200M

revenue generated by Alector top domains

Alector top domains revenue over 3 years

Revenue for Alector top domains

alector.com100M - 200M

See more with Sales Intelligence

Total visits to Alector's top domains

Understand Alector market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

alector.com6.1K

See more with Sales Intelligence

Avg. visit duration in Alector's top domains

Analyze Alector engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

alector.com00:00:30

See more with Sales Intelligence

Avg. pageviews on Alector's top domains

See how Alector keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

alector.com1.79

See more with Sales Intelligence

Alector top competitors by domain

Top similar sites in January 2026, ranked by their affinity

sagerx.comCompany NameSage Therapeutics, Inc.Employees201 - 500HQUnited States, Massachusetts, CambridgeAnnual revenue> $1BTotal visits8.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Alector

These are the website technologies, by industry, used by Alector top domains

Email Services (4)

G Suite

Content Management System (3)

WordPress

Conversion & Analytics (3)

Google Analytics

Widget (3)

Twemoji

More Technologies

7

See all

News & Signals from Alector

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAlector, Inc. attended event Goldman Sachs 46th Annual Global Healthcare Conference on Jun 10th '24.SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) - Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.

NewsAlector, Inc. attended event H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th '25.Additionally, Alector will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025, at 12:00 p.m. ET.

NewsAlector, Inc. is developing monoclonal antibody latozinemab.In another strategy, Alector, in collaboration with GSK, is developing the monoclonal antibody latozinemab (AL001), which works by blocking progranulin degradation to boost its availability.